tirzepatide surmount 3 being discontinued Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase trial Tirzepatide for maintenance of bodyweight

Semaglutide, available as branded Ozempic and Wegovy, and through PlexusDx as [Compounded Semaglutide] and [Oral Semaglutide], has demonstrated significant efficacy in clinical trials, helping individuals achieve substantial and sustained weight loss when combined with lifestyle modifications

Initiating treatment at the appropriate starting semaglutide doses sets the foundation, while subsequent adjustments cater to your response and needs

Some antidepressants can influence blood sugar levels, which is relevant for patients with diabetes who are taking medications like Ozempic

For context, NICE guidance on obesity pharmacotherapy including TA875 (semaglutide for weight management) and TA924 (tirzepatide for managing overweight and obesity) provides a useful framework for understanding how future agents might be positioned in the UK

In the UK, common examples include semaglutide (Ozempic for diabetes